Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764497 | 0.93 | P4HTM (0.35) | MMP2P4HTMALBBACE1EGLN1 | |
| SCHEMBL20764496 | 0.93 | P4HTM (0.35) | MMP2P4HTMALBBACE1EGLN1 | |
| SCHEMBL22099928 | 0.93 | MMP2 (0.41) | MMP2EGLN1CHRM2CHRM3MEN1 | |
| SCHEMBL20764567 | 0.90 | P4HTM (0.35) | MMP2P4HTMALBEGLN1F10 | |
| SCHEMBL20764565 | 0.90 | P4HTM (0.35) | MMP2P4HTMALBEGLN1F10 | |
| SCHEMBL20764474 | 0.85 | MMP2 (0.37) | MMP2EGLN1CHRM2CHRM3MEN1 | |
| SCHEMBL20764471 | 0.85 | MMP2 (0.37) | MMP2EGLN1CHRM2CHRM3MEN1 | |
| SCHEMBL20764547 | 0.85 | MMP2 (0.37) | MMP2CHRM2CHRM3MEN1KMT2A | |
| SCHEMBL20764544 | 0.85 | MMP2 (0.37) | MMP2CHRM2CHRM3MEN1KMT2A | |
| SCHEMBL20764587 | 0.83 | MMP2 (0.35) | MMP2EGLN1CHRM2CHRM3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | MMP2 1631/4885P4HTM 934/4885ALB 1404/4885 |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | CTH, CBS, SLC7A11 | MMP2 1862/4885P4HTM 989/4885ALB 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.